پنجشنبه 9 بهمن 1404
[Archive]
دوره 33، شماره 160 - ( 7-1404 )
جلد 33 شماره 160 صفحات 236-229 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Lateef S M, Abbas A A, Alosami M H. Infliximab Antibody Levels and Trough Concentration in Rheumatoid Arthritis: Exploring Therapeutic Response. J Adv Med Biomed Res 2025; 33 (160) :229-236
URL: http://journal.zums.ac.ir/article-1-7828-fa.html
URL: http://journal.zums.ac.ir/article-1-7828-fa.html
Infliximab Antibody Levels and Trough Concentration in Rheumatoid Arthritis: Exploring Therapeutic Response. Journal of Advances in Medical and Biomedical Research. 1404; 33 (160) :229-236
چکیده: (280 مشاهده)
Background and Aims: Infliximab (IFX) is a chimeric monoclonal antibody targeting tumor necrosis factor (TNF), developed to treat autoimmune diseases, including rheumatoid arthritis (RA). However, not all patients respond favorably to infliximab. The development of anti-infliximab antibodies (AIA) may contribute to treatment failure. This study aimed to investigate the association between AIA and infliximab trough levels with treatment response in patients with RA.
Materials and Methods: This cross-sectional study included 83 RA patients receiving infliximab (Remicade or Remsima) infusions at ≤ 6 months. Blood samples (3 ml) were collected prior to IFX infusion. Enzyme-linked immunosorbent assay (ELISA) kits were used to measure AIA, and infliximab trough concentration.
Results: Despite concurrent methotrexate therapy, many patients developed AIA (43.3 %). Infliximab trough concentration was higher in responders than non-responders but statistically not significant (P-value=0.114). Patients aged ≤40 years demonstrated a treatment response rate of 84.6%, compared with only 28.6% among those >60 years (P-value = 0.36). Additionally, male patients showed a higher response rate than females (P-value = 0.12).
Conclusion: The presence of AIA was associated with reduced treatment response in RA patients receiving infliximab. Higher infliximab trough levels correlated with better clinical outcomes. Age and sex may influence treatment efficacy, with younger patients and males showing better responses. Monitoring AIA and drug levels could help optimize therapeutic strategies in RA.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Clinical Medicine
دریافت: 1404/5/26 | پذیرش: 1404/8/10 | انتشار: 1404/8/20
دریافت: 1404/5/26 | پذیرش: 1404/8/10 | انتشار: 1404/8/20
فهرست منابع
1. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198-206. [DOI:10.1136/annrheumdis-2012-202603] [PMID]
2. Uke P, Maharaj A, Adebajo A. A review on the epidemiology of rheumatoid arthritis: An update and trends from current literature. Best Pract Res Clin Rheumatol. 2025;39(1):102036. [DOI:10.1016/j.berh.2025.102036] [PMID]
3. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. [DOI:10.3390/ijms22052719] [PMID] [PMCID]
4. Deka D. Pathogenesis and Current Treatment Strategies in Rheumatoid Arthritis: A Systematic Review Article. Ann Afr Med. 2025;24(3):532-9. [DOI:10.4103/aam.aam_11_24] [PMID] [PMCID]
5. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-602. [DOI:10.1056/NEJM200011303432202] [PMID]
6. Blumenauer BB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2002;2002(3):CD003785. [DOI:10.1002/14651858.CD004525]
7. van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis. 2009;68(8):1237-9. [DOI:10.1136/ard.2009.111682] [PMID]
8. Elliott MJ, Maini RN, Feldmann M, Long‐Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993;36(12):1681-90. [DOI:10.1002/art.1780361206] [PMID]
9. Riaz M, Rasool G, Yousaf R, Fatima H, Munir N, Ejaz H. Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis. Innate Immun. 2025;31:17534259251324820. [DOI:10.1177/17534259251324820] [PMID] [PMCID]
10. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biol Targets Ther. 2009:183-91. [DOI:10.2147/BTT.2009.3099] [PMID] [PMCID]
11. Siljehult F, Ärlestig L, Eriksson C, Rantapää-Dahlqvist S. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol. 2018;47(5):345-50. [DOI:10.1080/03009742.2018.1433232] [PMID]
12. Phung QT, Lee MV, Saad O, Cohen S, Li Y, Balasz M, et al. Immunogenicity Profiling of Biotherapeutics (Wiley Book - Bioanalytical Characterization of New Therapeutic Modalities). In Characterizing Biotherapeutics (eds J.R. Lill and W. Sandoval). 2025. Hoboken, NJ, U.S.: John Wiley & Sons, Inc. [DOI:10.1002/9781394236145.ch11]
13. Schaeverbeke T, Truchetet ME, Kostine M, Barnetche T, Bannwarth B, Richez C. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology. 2016;55(2):210-20. [DOI:10.1093/rheumatology/kev277] [PMID]
14. Pau A, Galliano I, Barnini E, Dini M, Pizzol A, Ponte A, et al. Involvement of HLADQA1* 05 in patients with inflammatory bowel disease treated with anti-TNF drugs. Medicina. 2025;61(1):102. [DOI:10.3390/medicina61010102] [PMID] [PMCID]
15. Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2018;67(5):818-26. [DOI:10.1136/gutjnl-2016-313071] [PMID]
16. Jumaah Fadhil Z, Abdul-Hassan Abbas A, Hadi Al-Osami M. The Influence of TNFRSF1B, PADI4, and miRNA 499 Gene Polymorphisms on Susceptibility and Responsiveness to TNF Inhibitors in Patients with Rheumatoid Arthritis. J Adv Med Biomed Res. 2023;31(147):381-90. [DOI:10.30699/jambs.31.147.381]
17. Kamel AH, Abbas AA, Humadi YA. Impact of Interleukin-6 Serum Levels and rs1800795 Promoter Polymorphism on Disease Activity and Tumor Necrosis Factor Inhibitor Efficacy in Rheumatoid Arthritis. Al-Rafidain J Med Sci. 2025;9(1):118-26. [DOI:10.54133/ajms.v9i1.2146]
18. Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med. 2013;11(1):94. [DOI:10.1186/1741-7015-11-94] [PMID] [PMCID]
19. Anaya JM, Lozada-Martinez ID, Torres I, Shoenfeld Y. Autoimmunity in centenarians. A paradox. J Transl Autoimmun. 2024;8:100237. [DOI:10.1016/j.jtauto.2024.100237] [PMID] [PMCID]
20. Lahaye C, Tatar Z, Dubost JJ, Tournadre A, Soubrier M. Management of inflammatory rheumatic conditions in the elderly. Rheumatology. 2019;58(5):748-64. [DOI:10.1093/rheumatology/key165] [PMID] [PMCID]
21. Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med. 2023;12(4):1630. [DOI:10.3390/jcm12041630] [PMID] [PMCID]
22. Lahaye C, Tatar Z, Dubost JJ, Soubrier M. Overview of biologic treatments in the elderly. Joint Bone Spine. 2015;82(3):154-60. [DOI:10.1016/j.jbspin.2014.10.012] [PMID]
23. Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101. [DOI:10.1177/1759720X221114101] [PMID] [PMCID]
24. Awni AA, Hamed ZO, Abbas AA, Abdulamir AS. Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis. Heliyon. 2023;9(6) e16814. [DOI:10.1016/j.heliyon.2023.e16814] [PMID] [PMCID]
25. Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol. 2011;335(1):14-29. [DOI:10.1016/j.mce.2010.05.018] [PMID]
26. Yang Q, Kennicott K, Zhu R, Kim J, Wakefield H, Studener K, et al. Sex hormone influence on female-biased autoimmune diseases hints at puberty as an important factor in pathogenesis. Front Pediatr. 2023;11:1051624. [DOI:10.3389/fped.2023.1051624] [PMID] [PMCID]
27. Selmi C, Gershwin ME. Sex and autoimmunity: proposed mechanisms of disease onset and severity. Expert Rev Clin Immunol. 2019;15(6):607-15. [DOI:10.1080/1744666X.2019.1606714] [PMID]
28. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, et al. Anti‐TNF and sex hormones. Ann N Y Acad Sci. 2006;1069(1):391-400. [DOI:10.1196/annals.1351.037] [PMID]
29. Maranini B, Bortoluzzi A, Silvagni E, Govoni M. Focus on sex and gender: what we need to know in the management of rheumatoid arthritis. J Pers Med. 2022;12(3):499. [DOI:10.3390/jpm12030499] [PMID] [PMCID]
30. Al-Karkhi MA, Al-Ani MM, Jassim NA. Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad. 2015;57(3):241-3. [DOI:10.32007/jfacmedbagdad.573372]
31. Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17(2):81-97. [DOI:10.1038/s41584-020-00540-8] [PMID]
32. Wolbink GJ, Voskuyl AE, Lems WF, De Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704-7. [DOI:10.1136/ard.2004.030452] [PMID] [PMCID]
33. Nakae K, Masui S, Yonezawa A, Hashimoto M, Watanabe R, Murata K, et al. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: a retrospective study based on KURAMA cohort data. PLoS One. 2021;16(10):e0258601. [DOI:10.1371/journal.pone.0258601] [PMID] [PMCID]
34. Dénarié D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H. Methotrexate reduced TNF bioactivity in rheumatoid arthritis patients treated with infliximab. Mediators Inflamm. 2017;2017(1):3708250. [DOI:10.1155/2017/3708250] [PMID] [PMCID]
35. Laeeq S, Reghefaoui T, Zahoor H, Yook JH, Rizwan M, Shahid NU, et al. Effectiveness of biologics and targeted synthetic disease‐modifying anti‐rheumatic drugs in conjunction with methotrexate for the treatment of early rheumatoid arthritis: A systematic review of randomized controlled trials. Musculoskeletal Care. 2022;20(3):471-86. [DOI:10.1002/msc.1612]
36. Finckh A, Dudler J, Wermelinger F, Ciurea A, Kyburz D, Gabay C, et al. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine. 2010;77(4):313-8. [DOI:10.1016/j.jbspin.2010.02.021] [PMID]
37. Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. Expert Rev Gastroenterol Hepatol. 2015;9(sup1):27-34. [DOI:10.1586/17474124.2015.1091307] [PMID]
38. Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res. 2021;51(5):358-73. [DOI:10.1002/jppr.1754]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
